|
1
|
Trefts E, Gannon M and Wasserman DH: The
liver. Curr Biol. 27:R1147–R1151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Embade N and Millet O: Molecular
determinants of chronic liver disease as studied by
NMR-Metabolomics. Curr Top Med Chem. 17:2752–2766. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang R, Tang R, Li B, Ma X, Schnabl B and
Tilg H: Gut microbiome, liver immunology, and liver diseases. Cell
Mol Immunol. 18:4–17. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Younossi Z, Tacke F, Arrese M, Chander
Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George
J, Fan J and Vos MB: Global Perspectives on Nonalcoholic Fatty
Liver Disease and Nonalcoholic Steatohepatitis. Hepatology.
69:2672–2682. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Diehl AM: Alcoholic liver disease. Clin
Liver Dis. 2:103–118. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang C, Ma C, Gong L, Guo Y, Fu K, Zhang
Y, Zhou H and Li Y: Macrophage Polarization and Its role in liver
disease. Front Immunol. 12:8030372021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gilgenkrantz H, Mallat A, Moreau R and
Lotersztajn S: Targeting cell-intrinsic metabolism for antifibrotic
therapy. J Hepatol. 74:1442–1454. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garcia-Martinez R, Caraceni P, Bernardi M,
Gines P, Arroyo V and Jalan R: Albumin: Pathophysiologic basis of
its role in the treatment of cirrhosis and its complications.
Hepatology. 58:1836–1846. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Araujo A, de Barros Lopes A, Rossi G,
da Silva GV, Ananias P, Ness S and Alvares-da-Silva MR: Low-dose
albumin in the treatment of spontaneous bacterial peritonitis:
Should we change the standard treatment? Gut. 61:1371–1372. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fernandez J, Navasa M, Garcia-Pagan JC,
G-Abraldes J, Jiménez W, Bosch J and Arroyo V: Effect of
intravenous albumin on systemic and hepatic hemodynamics and
vasoactive neurohormonal systems in patients with cirrhosis and
spontaneous bacterial peritonitis. J Hepatol. 41:384–390. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nguyen-Tat M, Jager J, Rey JW, Nagel M,
Labenz C, Wörns MA, Galle PR and Marquardt JU: Terlipressin and
albumin combination treatment in patients with hepatorenal syndrome
type 2. United European Gastroenterol J. 7:529–537. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wong F, Pappas SC, Curry MP, Reddy KR,
Rubin RA, Porayko MK, Gonzalez SA, Mumtaz K, Lim N, Simonetto DA,
et al: Terlipressin plus albumin for the treatment of type 1
Hepatorenal Syndrome. N Engl J Med. 384:818–828. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
China L, Freemantle N, Forrest E, Kallis
Y, Ryder SD, Wright G, Portal AJ, Becares Salles N, Gilroy DW and
O'Brien A; ATTIRE Trial Investigators, : A Randomized Trial of
Albumin Infusions in Hospitalized Patients with Cirrhosis. N Engl J
Med. 384:808–817. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Caraceni P, Domenicali M, Tovoli A, Napoli
L, Ricci CS, Tufoni M and Bernardi M: Clinical indications for the
albumin use: Still a controversial issue. Eur J Intern Med.
24:721–728. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jalan R, Schnurr K, Mookerjee RP, Sen S,
Cheshire L, Hodges S, Muravsky V, Williams R, Matthes G and Davies
NA: Alterations in the functional capacity of albumin in patients
with decompensated cirrhosis is associated with increased
mortality. Hepatology. 50:555–564. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ge P, Yang H, Lu J, Liao W, Du S, Xu Y, Xu
H, Zhao H, Lu X, Sang X, et al: Albumin binding function: The
potential earliest indicator for liver function damage.
Gastroenterol Res Pract. 2016:51207602016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Das S, Maras JS, Hussain MS, Sharma S,
David P, Sukriti S, Shasthry SM, Maiwall R, Trehanpati N, Singh TP
and Sarin SK: Hyperoxidized albumin modulates neutrophils to induce
oxidative stress and inflammation in severe alcoholic hepatitis.
Hepatology. 65:631–646. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rothschild MA, Oratz M and Schreiber SS:
Serum albumin. Hepatology. 8:385–401. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Caraceni P, O'Brien A and Gines P:
Long-term albumin treatment in patients with cirrhosis and ascites.
J Hepatol. 76:1306–1317. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bernardi M, Ricci CS and Zaccherini G:
Role of human albumin in the management of complications of liver
cirrhosis. J Clin Exp Hepatol. 4:302–311. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He XM and Carter DC: Atomic structure and
chemistry of human serum albumin. Nature. 358:209–215. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sugio S, Kashima A, Mochizuki S, Noda M
and Kobayashi K: Crystal structure of human serum albumin at 2.5 A
resolution. Protein Eng. 12:439–446. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oettl K and Stauber RE: Physiological and
pathological changes in the redox state of human serum albumin
critically influence its binding properties. Br J Pharmacol.
151:580–590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wada Y, Takeda Y and Kuwahata M: Potential
Role of Amino Acid/Protein Nutrition and Exercise in Serum Albumin
Redox State. Nutrients. 10:172017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prinsen BH and de Sain-van der Velden MG:
Albumin turnover: Experimental approach and its application in
health and renal diseases. Clin Chim Acta. 347:1–14. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Strauss AW, Donohue AM, Bennett CD, Rodkey
JA and Alberts AW: Rat liver preproalbumin: In vitro synthesis and
partial amino acid sequence. Proc Natl Acad Sci USA. 74:1358–1362.
1977. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Soeters PB, Wolfe RR and Shenkin A:
Hypoalbuminemia: Pathogenesis and clinical significance. JPEN J
Parenter Enteral Nutr. 43:181–193. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun X and Kaysen GA: Albumin and
transferrin synthesis are increased in H4 cells by serum from
analbuminemic or nephrotic rats. Kidney Int. 45:1381–1387. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li N, Zhou L, Zhang B, Dong P, Lin W, Wang
H, Xu R and Ding H: Recombinant human growth hormone increases
albumin and prolongs survival in patients with chronic liver
failure: A pilot open, randomized, and controlled clinical trial.
Dig Liver Dis. 40:554–559. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Castell JV, Gómez-Lechón MJ, David M,
Andus T, Geiger T, Trullenque R, Fabra R and Heinrich PC:
Interleukin-6 is the major regulator of acute phase protein
synthesis in adult human hepatocytes. FEBS Lett. 242:237–239. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bernardi M, Angeli P, Claria J, Moreau R,
Gines P, Jalan R, Caraceni P, Fernandez J, Gerbes AL, O'Brien AJ,
et al: Albumin in decompensated cirrhosis: New concepts and
perspectives. Gut. 69:1127–1138. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Merlot AM, Kalinowski DS and Richardson
DR: Unraveling the mysteries of serum albumin-more than just a
serum protein. Front Physiol. 5:2992014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chaudhury C, Mehnaz S, Robinson JM, Hayton
WL, Pearl DK, Roopenian DC and Anderson CL: The major
histocompatibility complex-related Fc receptor for IgG (FcRn) binds
albumin and prolongs its lifespan. J Exp Med. 197:315–322. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pyzik M, Rath T, Kuo TT, Win S, Baker K,
Hubbard JJ, Grenha R, Gandhi A, Krämer TD, Mezo AR, et al: Hepatic
FcRn regulates albumin homeostasis and susceptibility to liver
injury. Proc Natl Acad Sci USA. 114:E2862–E2871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schnitzer JE: gp60 is an albumin-binding
glycoprotein expressed by continuous endothelium involved in
albumin transcytosis. Am J Physiol. 262((1 Pt 2)): H246–H254.
1992.PubMed/NCBI
|
|
36
|
Schnitzer JE and Bravo J: High affinity
binding, endocytosis, and degradation of conformationall y modified
albumins. Potential role of gp30 and gp18 as novel scavenge r
receptors. J Biol Chem. 268:7562–7570. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Johansson E, Nielsen AD, Demuth H, Wiberg
C, Schjødt CB, Huang T, Chen J, Jensen S, Petersen J and Thygesen
P: Identification of binding sites on human serum albumin for
somapacitan, a long-acting growth hormone derivative. Biochemistry.
59:1410–1419. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schmidt MM, Townson SA, Andreucci AJ, King
BM, Schirmer EB, Murillo AJ, Dombrowski C, Tisdale AW, Lowden PA,
Masci AL, et al: Crystal structure of an HSA/FcRn complex reveals
recycling by competitive mimicry of HSA ligands at a pH-dependent
hydrophobic interface. Structure. 21:1966–1978. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leblanc Y, Berger M, Seifert A, Bihoreau N
and Chevreux G: Human serum albumin presents isoform variants with
altered neonatal Fc receptor interactions. Protein Sci.
28:1982–1992. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Baldassarre M, Naldi M, Zaccherini G,
Bartoletti M, Antognoli A, Laggetta M, Gagliardi M, Tufoni M,
Domenicali M, Waterstradt K, et al: Determination of effective
albumin in patients with decompensated cirrhosis: Clinical and
prognostic implications. Hepatology. 74:2058–2073. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun L, Yin H, Liu M, Xu G, Zhou X, Ge P,
Yang H and Mao Y: Impaired albumin function: A novel potential
indicator for liver function damage? Ann Med. 51:333–344. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brioschi M, Gianazza E, Mallia A, Zoanni
B, Altomare A, Martinez Fernandez A, Agostoni P, Aldini G and Banfi
C: S-Thiolation targets albumin in heart failure. Antioxidants
(Basel). 9:7632020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Colombo G, Clerici M, Giustarini D, Rossi
R, Milzani A and Dalle-Donne I: Redox albuminomics: Oxidized
albumin in human diseases. Antioxid Redox Signal. 17:1515–1527.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Roche M, Rondeau P, Singh NR, Tarnus E and
Bourdon E: The antioxidant properties of serum albumin. FEBS Lett.
582:1783–1787. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Turell L, Botti H, Carballal S, Radi R and
Alvarez B: Sulfenic acid-a key intermediate in albumin thiol
oxidation. J Chromatogr B Analyt Technol Biomed Life Sci.
877:3384–3392. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Turell L, Radi R and Alvarez B: The thiol
pool in human plasma: The central contribution of albumin to redox
processes. Free Radic Biol Med. 65:244–253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Altomare A, Baron G, Brioschi M, Longoni
M, Butti R, Valvassori E, Tremoli E, Carini M, Agostoni P, Vistoli
G, et al: N-Acetyl-Cysteine Regenerates Albumin Cys34 by a
thiol-disulfide breaking mechanism: An explanation of its
extracellular antioxidant activity. Antioxidants (Basel).
9:3672020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang X, Mao Z, Huang Y, Yan H, Yan Q, Hong
J, Fan J and Yao J: Reductively modified albumin attenuates
DSS-Induced mouse colitis through rebalancing systemic redox state.
Redox Biol. 41:1018812021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu S, Grigoryan H, Edmands WBM, Dagnino
S, Sinharay R, Cullinan P, Collins P, Chung KF, Barratt B, Kelly
FJ, et al: Cys34 adductomes differ between patients with chronic
lung or heart disease and healthy controls in Central London.
Environ Sci Technol. 52:2307–2313. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Terawaki H, Yoshimura K, Hasegawa T,
Matsuyama Y, Negawa T, Yamada K, Matsushima M, Nakayama M, Hosoya T
and Era S: Oxidative stress is enhanced in correlation with renal
dysfunction: Examination with the redox state of albumin. Kidney
Int. 66:1988–1993. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Taverna M, Marie AL, Mira JP and Guidet B:
Specific antioxidant properties of human serum albumin. Ann
Intensive Care. 3:42013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Stohs SJ and Bagchi D: Oxidative
mechanisms in the toxicity of metal ions. Free Radic Biol Med.
18:321–336. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Neuzil J and Stocker R: Bilirubin
attenuates radical-mediated damage to serum albumin. FEBS Lett.
331:281–284. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Carter DC and Ho JX: Structure of serum
albumin. Adv Protein Chem. 45:153–203. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Alcaraz-Quiles J, Casulleras M, Oettl K,
Titos E, Flores-Costa R, Duran-Güell M, López-Vicario C, Pavesi M,
Stauber RE, Arroyo V and Clària J: Oxidized albumin triggers a
cytokine storm in leukocytes through P38 mitogen-activated protein
kinase: Role in systemic inflammation in decompensated cirrhosis.
Hepatology. 68:1937–1952. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Casulleras M, Flores-Costa R, Duran-Güell
M, Alcaraz-Quiles J, Sanz S, Titos E, López-Vicario C, Fernández J,
Horrillo R, Costa M, et al: Albumin internalizes and inhibits
endosomal TLR signaling in leukocytes from patients with
decompensated cirrhosis. Sci Transl Med. 12:eaax51352020.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen TA, Tsao YC, Chen A, Lo GH, Lin CK,
Yu HC, Cheng LC, Hsu PI and Tsai WL: Effect of intravenous albumin
on endotoxin removal, cytokines, and nitric oxide production in
patients with cirrhosis and spontaneous bacterial peritonitis.
Scand J Gastroenterol. 44:619–625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Delaney AP, Dan A, McCaffrey J and Finfer
S: The role of albumin as a resuscitation fluid for patients with
sepsis: A systematic review and meta-analysis. Crit Care Med.
39:386–391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Anraku M, Yamasaki K, Maruyama T,
Kragh-Hansen U and Otagiri M: Effect of oxidative stress on the
structure and function of human serum albumin. Pharm Res.
18:632–639. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Vairappan B: Endothelial dysfunction in
cirrhosis: Role of inflammation and oxidative stress. World J
Hepatol. 7:443–459. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Magzal F, Sela S, Szuchman-Sapir A, Tamir
S, Michelis R and Kristal B: In-vivo oxidized albumin-a
pro-inflammatory agent in hypoalbuminemia. PLoS One.
12:e01777992017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Keszler A, Zhang Y and Hogg N: Reaction
between nitric oxide, glutathione, and oxygen in the presence and
absence of protein: How are S-nitrosothiols formed? Free Radic Biol
Med. 48:55–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gow AJ, Buerk DG and Ischiropoulos H: A
novel reaction mechanism for the formation of S-nitrosothiol in
vivo. J Biol Chem. 272:2841–2845. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Naldi M, Baldassarre M, Domenicali M,
Bartolini M and Caraceni P: Structural and functional integrity of
human serum albumin: Analytical approaches and clinical relevance
in patients with liver cirrhosis. J Pharm Biomed Anal. 144:138–153.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Berlett BS and Stadtman ER: Protein
oxidation in aging, disease, and oxidative stress. J Biol Chem.
272:20313–20316. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Bhat A, Das S, Yadav G, Chaudhary S, Vyas
A, Islam M, Gupta AC, Bajpai M, Maiwall R, Maras JS and Sarin SK:
Hyperoxidized albumin modulates platelets and promotes inflammation
through CD36 receptor in severe alcoholic hepatitis. Hepatol
Commun. 4:50–65. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Stewart AJ, Blindauer CA, Berezenko S,
Sleep D, Tooth D and Sadler PJ: Role of Tyr84 in controlling the
reactivity of Cys34 of human albumin. FEBS J. 272:353–362. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kawakami A, Kubota K, Yamada N, Tagami U,
Takehana K, Sonaka I, Suzuki E and Hirayama K: Identification and
characterization of oxidized human serum albumin. A slight
structural change impairs its ligand-binding and antioxidant
functions. FEBS J. 273:3346–3357. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yamasaki K, Chuang VT, Maruyama T and
Otagiri M: Albumin-drug interaction and its clinical implication.
Biochim Biophys Acta. 1830:5435–5443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Oettl K, Birner-Gruenberger R,
Spindelboeck W, Stueger HP, Dorn L, Stadlbauer V, Putz-Bankuti C,
Krisper P, Graziadei I, Vogel W, et al: Oxidative albumin damage in
chronic liver failure: Relation to albumin binding capacity, liver
dysfunction and survival. J Hepatol. 59:978–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Nagumo K, Tanaka M, Chuang VT, Setoyama H,
Watanabe H, Yamada N, Kubota K, Tanaka M, Matsushita K, Yoshida A,
et al: Cys34-cysteinylated human serum albumin is a sensitive
plasma marker in oxidative stress-related chronic diseases. PLoS
One. 9:e852162014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Brownlee M, Vlassara H and Cerami A:
Nonenzymatic glycosylation and the pathogenesis of diabetic
complications. Ann Intern Med. 101:527–537. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Cohen MP: Intervention strategies to
prevent pathogenetic effects of glycated albumin. Arch Biochem
Biophys. 419:25–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Rabbani G and Ahn SN: Structure, enzymatic
activities, glycation and therapeutic potential of human serum
albumin: A natural cargo. Int J Biol Macromol. 123:979–990. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Rondeau P and Bourdon E: The glycation of
albumin: Structural and functional impacts. Biochimie. 93:645–658.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ding A, Ojingwa JC, McDonagh AF,
Burlingame AL and Benet LZ: Evidence for covalent binding of acyl
glucuronides to serum albumin via an imine mechanism as revealed by
tandem mass spectrometry. Proc Natl Acad Sci USA. 90:3797–3801.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Tabata F, Wada Y, Kawakami S and Miyaji K:
Serum albumin redox states: More than oxidative stress biomarker.
Antioxidants (Basel). 10:5032021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Thornalley PJ, Langborg A and Minhas HS:
Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the
glycation of proteins by glucose. Biochem J. 344(Pt 1(Pt 1)):
109–116. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Brownlee M, Cerami A and Vlassara H:
Advanced glycosylation end products in tissue and the biochemical
basis of diabetic complications. N Engl J Med. 318:1315–1321. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ahmed N, Dobler D, Dean M and Thornalley
PJ: Peptide mapping identifies hotspot site of modification in
human serum albumin by methylglyoxal involved in ligand binding and
esterase activity. J Biol Chem. 280:5724–5732. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Fuentes-Lemus E, Reyes JS, Lopez-Alarcon C
and Davies MJ: Crowding modulates the glycation of plasma proteins:
In vitro analysis of structural modifications to albumin and
transferrin and identification of sites of modification. Free Radic
Biol Med. 193((Pt 2)): 551–566. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Bohney JP and Feldhoff RC: Effects of
nonenzymatic glycosylation and fatty acids on tryptophan binding to
human serum albumin. Biochem Pharmacol. 43:1829–1834. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Barnaby OS, Cerny RL, Clarke W and Hage
DS: Comparison of modification sites formed on human serum albumin
at various stages of glycation. Clin Chim Acta. 412:277–285. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Okabe N and Hashizume N: Drug binding
properties of glycosylated human serum albumin as measured by
fluorescence and circular dichroism. Biol Pharm Bull. 17:16–21.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Baraka-Vidot J, Guerin-Dubourg A, Bourdon
E and Rondeau P: Impaired drug-binding capacities of in vitro and
in vivo glycated albumin. Biochimie. 94:1960–1967. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Nakajou K, Watanabe H, Kragh-Hansen U,
Maruyama T and Otagiri M: The effect of glycation on the structure,
function and biological fate of human serum albumin as revealed by
recombinant mutants. Biochim Biophys Acta. 1623:88–97. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Joseph JS and Hage DS: The effects of
glycation on the binding of human serum albumin to warfarin and
L-tryptophan. J Pharm Biomed Anal. 53:811–818. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Shaklai N, Garlick RL and Bunn HF:
Nonenzymatic glycosylation of human serum albumin alters its
conformation and function. J Biol Chem. 259:3812–3817. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Barzegar A, Moosavi-Movahedi AA,
Sattarahmady N, Hosseinpour-Faizi MA, Aminbakhsh M, Ahmad F,
Saboury AA, Ganjali MR and Norouzi P: Spectroscopic studies of the
effects of glycation of human serum albumin on L-Trp binding.
Protein Pept Lett. 14:13–18. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Mendez DL, Jensen RA, McElroy LA, Pena JM
and Esquerra RM: The effect of non-enzymatic glycation on the
unfolding of human serum albumin. Arch Biochem Biophys. 444:92–99.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Watanabe A, Matsuzaki S, Moriwaki H,
Suzuki K and Nishiguchi S: Problems in serum albumin measurement
and clinical significance of albumin microheterogeneity in
cirrhotics. Nutrition. 20:351–357. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Horiuchi S: The liver is the main site for
metabolism of circulating advanced glycation end products. J
Hepatol. 36:123–125. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Patche J, Girard D, Catan A, Boyer F, Dobi
A, Planesse C, Diotel N, Guerin-Dubourg A, Baret P, Bravo SB, et
al: Diabetes-induced hepatic oxidative stress: A new pathogenic
role for glycated albumin. Free Radic Biol Med. 102:133–148. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Chen Z, Chen Q, Huang J, Gong W, Zou Y,
Zhang L, Liu P and Huang H: CK2α promotes advanced glycation end
products-induced expressions of fibronectin and intercellular
adhesion molecule-1 via activating MRTF-A in glomerular mesangial
cells. Biochem Pharmacol. 148:41–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Scavello F, Zeni F, Milano G, Macrì F,
Castiglione S, Zuccolo E, Scopece A, Pezone G, Tedesco CC, Nigro P,
et al: Soluble receptor for advanced glycation end-products
regulates age-associated cardiac fibrosis. Int J Biol Sci.
17:2399–2416. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Goodwin M, Herath C, Jia Z, Leung C,
Coughlan MT, Forbes J and Angus P: Advanced glycation end products
augment experimental hepatic fibrosis. J Gastroenterol Hepatol.
28:369–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Stamler JS, Jaraki O, Osborne J, Simon DI,
Keaney J, Vita J, Singel D, Valeri CR and Loscalzo J: Nitric oxide
circulates in mammalian plasma primarily as an S-nitroso adduct of
serum albumin. Proc Natl Acad Sci USA. 89:7674–7677. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Tsikas D: Extra-platelet
low-molecular-mass thiols mediate the inhibitory action of
S-nitrosoalbumin on human platelet aggregation via
S-transnitrosylation of the platelet surface. Amino Acids.
53:563–573. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Burczynski FJ, Wang GQ and Hnatowich M:
Effect of nitric oxide on albumin-palmitate binding. Biochem
Pharmacol. 49:91–96. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
McNaughton L, Puttagunta L,
Martinez-Cuesta MA, Kneteman N, Mayers I, Moqbel R, Hamid Q and
Radomski MW: Distribution of nitric oxide synthase in normal and
cirrhotic human liver. Proc Natl Acad Sci USA. 99:17161–17166.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Jiao J, Mandapati S, Skipper PL,
Tannenbaum SR and Wishnok JS: Site-selective nitration of tyrosine
in human serum albumin by peroxynitrite. Anal Biochem. 293:43–52.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Andersen JT, Dalhus B, Cameron J, Daba MB,
Plumridge A, Evans L, Brennan SO, Gunnarsen KS, Bjørås M, Sleep D
and Sandlie I: Structure-based mutagenesis reveals the
albumin-binding site of the neonatal Fc receptor. Nat Commun.
3:6102012. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Bar-Or D, Curtis G, Rao N, Bampos N and
Lau E: Characterization of the Co(2+) and Ni(2+) binding amino-acid
residues of the N-terminus of human albumin. An insight into the
mechanism of a new assay for myocardial ischemia. Eur J Biochem.
268:42–47. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Naldi M, Giannone FA, Baldassarre M,
Domenicali M, Caraceni P, Bernardi M and Bertucci C: A fast and
validated mass spectrometry method for the evaluation of human
serum albumin structural modifications in the clinical field. Eur J
Mass Spectrom (Chichester). 19:491–496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Bar-Or D, Rael LT, Bar-Or R, Slone DS and
Craun ML: The formation and rapid clearance of a truncated albumin
species in a critically ill patient. Clin Chim Acta. 365:346–349.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Bar-Or D, Winkler JV, Vanbenthuysen K,
Harris L, Lau E and Hetzel FW: Reduced albumin-cobalt binding with
transient myocardial ischemia after elective percutaneous
transluminal coronary angioplasty: A preliminary comparison to
creatine kinase-MB, myoglobin, and troponin I. Am Heart J.
141:985–991. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Ogasawara Y, Namai T, Togawa T and Ishii
K: Formation of albumin dimers induced by exposure to peroxides in
human plasma: A possible biomarker for oxidative stress. Biochem
Biophys Res Commun. 340:353–358. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Naldi M, Baldassarre M, Nati M, Laggetta
M, Giannone FA, Domenicali M, Bernardi M, Caraceni P and Bertucci
C: Mass spectrometric characterization of human serum albumin
dimer: A new potential biomarker in chronic liver diseases. J Pharm
Biomed Anal. 112:169–175. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Chubarov A, Spitsyna A, Krumkacheva O,
Mitin D, Suvorov D, Tormyshev V, Fedin M, Bowman MK and
Bagryanskaya E: Reversible dimerization of human serum albumin.
Molecules. 26:1082020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Baldassarre M, Domenicali M, Naldi M,
Laggetta M, Giannone FA, Biselli M, Patrono D, Bertucci C, Bernardi
M and Caraceni P: Albumin homodimers in patients with cirrhosis:
Clinical and prognostic relevance of a novel identified structural
alteration of the molecule. Sci Rep. 6:359872016. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Bar-Or R, Rael LT and Bar-Or D:
Dehydroalanine derived from cysteine is a common post-translational
modification in human serum albumin. Rapid Commun Mass Spectrom.
22:711–716. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Domenicali M, Baldassarre M, Giannone FA,
Naldi M, Mastroroberto M, Biselli M, Laggetta M, Patrono D,
Bertucci C, Bernardi M and Caraceni P: Posttranscriptional changes
of serum albumin: Clinical and prognostic significance in
hospitalized patients with cirrhosis. Hepatology. 60:1851–1860.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Paar M, Fengler VH, Rosenberg DJ, Krebs A,
Stauber RE, Oettl K and Hammel M: Albumin in patients with liver
disease shows an altered conformation. Commun Biol. 4:7312021.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Oettl K, Stadlbauer V, Petter F,
Greilberger J, Putz-Bankuti C, Hallström S, Lackner C and Stauber
RE: Oxidative damage of albumin in advanced liver disease. Biochim
Biophys Acta. 1782:469–473. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Rashid G, Benchetrit S, Fishman D and
Bernheim J: Effect of advanced glycation end-products on gene
expression and synthesis of TNF-alpha and endothelial nitric oxide
synthase by endothelial cells. Kidney Int. 66:1099–1106. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Arroyo V and Claria J: Acute-on-Chronic
liver failure, human serum albumin, and immune modulation: The
beginning of an exciting adventure. Clin Gastroenterol Hepatol.
16:633–636. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
O'Brien AJ, Fullerton JN, Massey KA, Auld
G, Sewell G, James S, Newson J, Karra E, Winstanley A, Alazawi W,
et al: Immunosuppression in acutely decompensated cirrhosis is
mediated by prostaglandin E2. Nat Med. 20:518–523. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Trebicka J, Amoros A, Pitarch C, Titos E,
Alcaraz-Quiles J, Schierwagen R, Deulofeu C, Fernandez-Gomez J,
Piano S, Caraceni P, et al: Addressing profiles of systemic
inflammation across the different clinical phenotypes of acutely
decompensated cirrhosis. Front Immunol. 10:4762019. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Claria J, Stauber RE, Coenraad MJ, Moreau
R, Jalan R, Pavesi M, Amorós À, Titos E, Alcaraz-Quiles J, Oettl K,
et al: Systemic inflammation in decompensated cirrhosis:
Characterization and role in acute-on-chronic liver failure.
Hepatology. 64:1249–1264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Naldi M, Baldassarre M, Domenicali M,
Giannone FA, Bossi M, Montomoli J, Sandahl TD, Glavind E, Vilstrup
H, Caraceni P and Bertucci C: Mass spectrometry characterization of
circulating human serum albumin microheterogeneity in patients with
alcoholic hepatitis. J Pharm Biomed Anal. 122:141–147. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Das S, Hussain MS, Maras JS, Kumar J,
Shasthry SM, Nayak S, Arora V, Vijayaraghavan R, Sharma S, Maiwall
R and Sarin SK: Modification patterns of urinary albumin correlates
with serum albumin and outcome in severe alcoholic hepatitis. J
Clin Gastroenterol. 53:e243–e252. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Pawlak M, Lefebvre P and Staels B:
Molecular mechanism of PPARα action and its impact on lipid
metabolism, inflammation and fibrosis in non-alcoholic fatty liver
disease. J Hepatol. 62:720–733. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Sun L, Wang Q, Liu M, Xu G, Yin H, Wang D,
Xie F, Jin B, Jin Y, Yang H, et al: Albumin binding function is a
novel biomarker for early liver damage and disease progression in
non-alcoholic fatty liver disease. Endocrine. 69:294–302. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Santos JC, Valentim IB, de Araujo OR,
Ataide Tda R and Goulart MO: Development of nonalcoholic
hepatopathy: Contributions of oxidative stress and advanced
glycation end products. Int J Mol Sci. 14:19846–19866. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Priken K, Tapia G, Cadagan C, Quezada N,
Torres J, D'Espessailles A and Pettinelli P: Higher hepatic
advanced glycation end products and liver damage markers are
associated with nonalcoholic steatohepatitis. Nutr Res. 104:71–81.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Palma-Duran SA, Kontogianni MD,
Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, Papatheodoridis
G and Combet E: Serum levels of advanced glycation end-products
(AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify
non-alcoholic fatty liver disease in age-, sex- and BMI-matched
normo-glycemic adults. Metabolism. 83:120–127. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Pereira ENGDS, Paula DP, de Araujo BP, da
Fonseca MJM, Diniz MFHS, Daliry A and Griep RH: Advanced glycation
end product: A potential biomarker for risk stratification of
non-alcoholic fatty liver disease in ELSA-Brasil study. World J
Gastroenterol. 27:4913–4928. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Yavuz F, Biyik M, Asil M, Dertli R, Demir
A, Polat H, Uysal S and Ataseven H: Serum ischemic modified albumin
(IMA) concentration and IMA/albumin ratio in patients with
hepatitis B-related chronic liver diseases. Turk J Med Sci.
47:947–953. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Cakir M, Karahan SC, Mentese A, Sag E,
Cobanoglu U, Polat TB and Erduran E: Ischemia-Modified albumin
levels in children with chronic liver disease. Gut Liver. 6:92–97.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
European Association for the Study of the
Liver. Electronic address, . simpleeasloffice@easloffice.eu;
European Association for the Study of the Liver: EASL Clinical
Practice Guidelines for the management of patients with
decompensated cirrhosis. J Hepatol. 69:406–460. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Bai Z, Méndez-Sánchez N, Romeiro FG,
Mancuso A, Philips CA, Tacke F, Basaranoglu M, Primignani M,
Ibrahim M, Wong YJ, et al: Use of albumin infusion for
cirrhosis-related complications: An international position
statement. JHEP Rep. 5:1007852023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Sort P, Navasa M, Arroyo V, Aldeguer X,
Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G,
Guevara M, et al: Effect of intravenous albumin on renal impairment
and mortality in patients with cirrhosis and spontaneous bacterial
peritonitis. N Engl J Med. 341:403–409. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Bortoluzzi A, Ceolotto G, Gola E, Sticca
A, Bova S, Morando F, Piano S, Fasolato S, Rosi S, Gatta A and
Angeli P: Positive cardiac inotropic effect of albumin infusion in
rodents with cirrhosis and ascites: Molecular mechanisms.
Hepatology. 57:266–276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Fernandez J, Claria J, Amoros A, Aguilar
F, Castro M, Casulleras M, Acevedo J, Duran-Güell M, Nuñez L, Costa
M, et al: Effects of albumin treatment on systemic and portal
hemodynamics and systemic inflammation in patients with
decompensated cirrhosis. Gastroenterology. 157:149–162. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Caraceni P, Riggio O, Angeli P,
Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S,
Svegliati-Baroni G, et al: Long-term albumin administration in
decompensated cirrhosis (ANSWER): An open-label randomised trial.
Lancet. 391:2417–2429. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Alukal JJ, John S and Thuluvath PJ:
Hyponatremia in Cirrhosis: An Update. Am J Gastroenterol.
115:1775–1785. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Teh KB, Loo JH, Tam YC and Wong YJ:
Efficacy and safety of albumin infusion for overt hepatic
encephalopathy: A systematic review and meta-analysis. Dig Liver
Dis. 53:817–823. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Rose CF, Amodio P, Bajaj JS, Dhiman RK,
Montagnese S, Taylor-Robinson SD, Vilstrup H and Jalan R: Hepatic
encephalopathy: Novel insights into classification, pathophysiology
and therapy. J Hepatol. 73:1526–1547. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
China L, Becares N, Rhead C, Tittanegro T,
Freemantle N and O'Brien A: Targeted albumin infusions do not
improve systemic inflammation or cardiovascular function in
decompensated cirrhosis. Clin Transl Gastroenterol. 13:e004762022.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Sandi BB, Leao GS, de Mattos AA and de
Mattos AZ: Long-term albumin administration in patients with
cirrhosis and ascites: A meta-analysis of randomized controlled
trials. J Gastroenterol Hepatol. 36:609–617. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Plantier JL, Duretz V, Devos V, Urbain R
and Jorieux S: Comparison of antioxidant properties of different
therapeutic albumin preparations. Biologicals. 44:226–233. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Mikkat S, Dominik A, Stange J and Eggert
M: Comparison of accompanying proteins in different therapeutic
human serum albumin preparations. Biologicals. 64:41–48. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Bar-Or D, Bar-Or R, Rael LT, Gardner DK,
Slone DS and Craun ML: Heterogeneity and oxidation status of
commercial human albumin preparations in clinical use. Crit Care
Med. 33:1638–1641. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Berezenko S: Heterogeneity and oxidation
status of commercial human albumin preparations in clinical use.
Crit Care Med. 34:1291author reply 1291. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Cheungpasitporn W, Thongprayoon C, Zoghby
ZM and Kashani K: MARS: Should i use it? Adv Chronic Kidney Dis.
28:47–58. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Wallon G, Guth C, Guichon C, Thevenon S,
Gazon M, Viale JP, Schoeffler M, Duperret S and Aubrun F:
Extracorporeal albumin dialysis in liver failure with MARS and
SPAD: A Randomized crossover trial. Blood Purif. 51:243–250. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Klammt S, Mitzner SR, Stange J, Loock J,
Heemann U, Emmrich J, Reisinger EC and Schmidt R: Improvement of
impaired albumin binding capacity in acute-on-chronic liver failure
by albumin dialysis. Liver Transpl. 14:1333–1339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Oettl K, Stadlbauer V, Krisper P and
Stauber RF: Effect of extracorporeal liver support by molecular
adsorbents recirculating system and Prometheus on redox state of
albumin in acute-on-chronic liver failure. Ther Apher Dial.
13:431–436. 2009. View Article : Google Scholar : PubMed/NCBI
|
